

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims

Claims 1-26 (Cancelled)

Claim 27 (Previously presented) An isolated polypeptide which is in N-glycosylated form and is useful in the treatment of ulcers, said polypeptide having an amino acid sequence according to SEQ ID NO:1

Glu Lys Pro Ser Pro Cys Gln Cys Ser Arg Leu Ser Pro His Asn Arg Thr Asn Cys Gly Phe Pro Gly Ile Thr Ser Asp Gln Cys Phe Asp Asn Gly Cys Cys Phe Asp Ser Ser Val Thr Gly Val Pro Trp Cys Phe His Pro Leu Pro Lys Gln Glu Ser Asp Gln Cys Val Met Glu Val Ser Asp Arg Arg Asn Cys Gly Tyr Pro Gly Ile Ser Pro Glu Glu Cys Ala Ser Arg Lys Cys Cys Phe Ser Asn Phe Ile Phe Glu Val Pro Trp Cys Phe Phe Pro Asn Ser Val Glu Asp Cys His Tyr

or an amino acid sequence that is a homologue of SEQ ID NO:1 where the sequence of said homologue

- A) has six disulphide bonds that form two trefoil domains, where the 12 cysteines that form the six disulphide bonds are in the configuration 1-5, 2-4, 3-6, 7-11, 8-10 and 9-12, and
- B) is encoded by a nucleic acid sequence that is at least 60 % homologous to a nucleic acid sequence that encodes SEQ ID NO:1 and that hybridizes under high stringency conditions to the nucleic acid sequence that encodes SEQ ID NO:1.

Claim 28 (Previously presented) The polypeptide of claim 27 wherein said polypeptide is glycosylated at an Asn present at position 15 of the amino acid sequence of said polypeptide.

Claim 29 (Previously presented) The polypeptide of claim 27, wherein the glycosylated form comprises a glycosylated side chain comprising at least one hexose unit.

Claim 30 (Previously presented) The polypeptide of claim 29, wherein the glycosylated side chain comprises at least one mannose unit.

Claim 31 (Previously presented) The polypeptide of claim 30, wherein the glycosylated side chain comprises 13-17 mannose units.

Claim 32 (Previously presented) The polypeptide of claim 27, wherein the glycosylated form comprises at least one unit of N-acetyl glucosamine (GlcNAc).

Claim 33 (Previously presented) The polypeptide of claim 27, wherein the glycosylated form comprises $(\text{GlcNAc})_2(\text{Man})_{10-15}$.

Claims 34-35 (Cancelled)

Claim 36 (Previously presented) A pharmaceutical composition comprising the polypeptide of claim 27 together with a pharmaceutically acceptable carrier or excipient.

Claims 37-39 (Cancelled)

Claim 40 (Previously presented) The polypeptide of claim 27, wherein said polypeptide has an amino acid sequence according to SEQ ID NO:1.

Claim 41 (Previously presented) A pharmaceutical composition comprising the polypeptide of claim 40 together with a pharmaceutically acceptable carrier or excipient.

Claim 42 (Previously presented) The polypeptide of claim 27, wherein the polypeptide has an amino acid sequence that is a homologue of SEQ ID NO:1.

Claim 43 (Previously presented) The polypeptide of claim 42, wherein the homologue amino acid sequence contains 39 amino acids in the first trefoil domain.

Claim 44 (Previously presented) The polypeptide of claim 43, wherein the 39 amino acids in the first trefoil domain of the homologue amino acid sequence are identical to amino acids 8-46 of SEQ ID NO:1 except for two amino acid substitutions.

Claim 45 (Previously presented) The polypeptide of claim 44, wherein the 39 amino acids in the first trefoil domain of the homologue amino acid sequence are identical to amino acids 8-46 of SEQ ID NO:1.

Claim 46 (Previously presented) The polypeptide of claim 42, wherein the homologue amino acid sequence contains 38 amino acids in the second trefoil domain.

Claim 47 (Previously presented) The polypeptide of claim 46, wherein the 38 amino acids in the second trefoil domain of the homologue amino acid sequence are identical to amino acids 58-95 of SEQ ID NO:1 except for two amino acid substitutions.

Claim 48 (Previously presented) The polypeptide of claim 47, wherein the 38 amino acids in the second trefoil domain of the homologue amino acid sequence are identical to amino acids 58-95 of SEQ ID NO:1.

Claim 49 (Previously presented) The polypeptide of claim 43, wherein the homologue amino acid sequence contains 38 amino acids in the second trefoil domain and the 38 amino acids in the second trefoil domain of the homologue amino acid sequence are identical to amino acids 58-95 of SEQ ID NO:1 except for two amino acid substitutions.

Claim 50 (Previously presented) The polypeptide of claim 49, wherein the 38 amino acids in the second trefoil domain of the homologue amino acid sequence are identical to amino acids 58-95 of SEQ ID NO:1.

Claim 51 (Previously presented) The polypeptide of claim 50, wherein the 39 amino acids in the first trefoil domain of the homologue amino acid sequence are identical to amino acids 8-46 of SEQ ID NO:1.

Claim 52 (Previously presented) The polypeptide of claim 49, wherein the 39 amino acids in the first trefoil domain of the homologue amino acid sequence are identical to amino acids 8-46 of SEQ ID NO:1.

Claim 53 (Previously presented) The polypeptide of claim 42, wherein the homologue amino acid sequence is identical to SEQ ID NO:1 except for two amino acid substitutions.

Claim 54 (Previously presented) The polypeptide of claim 53, wherein the two amino acid substitutions are in the first trefoil domain of the homologue amino acid sequence.

Claim 55 (Previously presented) The polypeptide of claim 53, wherein the two amino acid substitutions are in the second trefoil domain of the homologue amino acid sequence.

Claim 56 (Previously presented) The polypeptide of claim 42, wherein the homologue amino acid sequence is identical to SEQ ID NO:1 except for deletion of one or more amino acids at either end of SEQ ID NO:1.

Claim 57 (Previously presented) The polypeptide of claim 56, wherein the homologue amino acid sequence is identical to SEQ ID NO:1 except for deletion of one amino acid at either end of SEQ ID NO:1.

Claim 58 (Previously presented) The polypeptide of claim 42, wherein the homologue amino acid sequence is identical to SEQ ID NO:1 except for addition of one or more amino acids at either end of SEQ ID NO:1.

Claim 59 (Previously presented) The polypeptide of claim 58, wherein the homologue amino acid sequence is identical to SEQ ID NO:1 except for addition of one amino acid at either end of SEQ ID NO:1.

Claim 60 (Previously presented) The polypeptide of claim 40, wherein said polypeptide is glycosylated at an Asn present at position 15 of the amino acid sequence of said polypeptide.

Claim 61 (Previously presented) The polypeptide of claim 60, wherein the glycosylated form comprises a glycosylated side chain comprising at least one hexose unit.

Claim 62 (Previously presented) The polypeptide of claim 61, wherein the glycosylated side chain comprises at least one mannose unit.

Claim 63 (Previously presented) The polypeptide of claim 62, wherein the glycosylated side chain comprises 13-17 mannose units.

Claim 64 (Previously presented) The polypeptide of claim 63, wherein the glycosylated form comprises at least one unit of N-acetyl glucosamine (GlcNAc).

Claim 65 (Previously presented) The polypeptide of claim 64, wherein the glycosylated form comprises $(\text{GlcNAc})_2(\text{Man})_{10-15}$.